INTRODUCTION: For years, mifepristone combined with misoprostol was considered standard treatment for first-trimester abortions. In 2018, ACOG finally updated its recommendations to include mifepristone for management of early pregnancy loss (EPL). Adoption of this has met resistance. One perceived barrier to the provision of mifepristone is cost. Our aim is to determine if mifepristone pretreatment adversely affects cost of medical management of EPL. METHODS: Decision tree analyses were constructed comparing costs of combination therapy versus monotherapy in multiple scenarios weighing provider practice, patient income, and surgical evacuation modalities for failed medical management. Rates of completed medical evacuation for each were obtained from recent randomized controlled trials. RESULTS: In nearly every scenario, combination therapy was favored over monotherapy. When surgical costs were higher, combined therapy was highly favored ($254.90 vs $391.60 per patient, 54% greater for monotherapy). Only when office manual vacuum aspiration was exclusively used and the patient population received minimum Federal wages was monotherapy minimally favored ($149.91 vs $152.54 per patient, 2% less for monotherapy). For equality of cost to occur in the various scenarios, the difference in completion rates between combination therapy and monotherapy needed to be between 5.6% and 15.2% - levels significantly less than that found in the literature (14.7% to 30.9%). CONCLUSION: Mifepristone combined with misoprostol is overall more cost effective than monotherapy and therefore cost should not be a deterrent to its adoption.
Read full abstract